CSF ACR 2023 RA Highlights
- No tags were found...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>ACR</strong> <strong>2023</strong><br />
Congress Preview<br />
Rheumatoid Arthritis<br />
Faculty Introduction<br />
Dear Colleagues,<br />
Welcome to this year’s selection of <strong>ACR</strong> abstracts on <strong>RA</strong> and my ‘<strong>Highlights</strong>’. We have selected abstracts that<br />
cover a range of key topics in the management of rheumatoid arthritis.<br />
On Sunday, there is an abstract session on the mechanisms of action of novel <strong>RA</strong> therapies. This session includes<br />
talks by Peter Taylor (0839) and Xiaofeng Zeng (0840). In addition, there are several posters about <strong>RA</strong> therapies,<br />
including upadacitinib (0424, 0429, 0459), baricitinib (0450), and a novel synthetic DMARD (0444). I encourage<br />
you to have a look at them and the other posters I recommend when you can.<br />
On Monday, Kenneth Derr presents ‘Population Pharmacokinetic/Pharmacodynamic Modeling of Dazodalibep, a<br />
CD40L Antagonist, in Healthy Volunteers and Patients with Rheumatoid Arthritis and Sjogren’s Syndrome’ as part of<br />
the ‘Sjögren’s Syndrome – Basic & Clinical Science Poster I’ session. There are also more posters about <strong>RA</strong> therapies<br />
on Monday, with Kevin Winthrop (1325) and Xavier Mariette (1343) presenting long-term safety data on filgotinib.<br />
Tuesday features poster presentations of Phase 2 studies of peresolimab (2176) and tofacitinib and adalimumab<br />
(2157). During the ‘<strong>RA</strong> – Treatments Poster III’ session, Paul Emery presents ‘Safety and Efficacy of Filgotinib:<br />
An Update from the DARWIN 3 Phase 2 Long-term Extension with a Maximum of 8.2 Years of Exposure.’<br />
These posters are a great way to gain a deeper appreciation of the ways <strong>RA</strong> therapies are improving.<br />
The congress concludes on Wednesday and includes scientific sessions, late-breaking abstracts, and industrysupported<br />
sessions. These final offerings will be of great interest for anyone looking for the cutting-edge<br />
developments in <strong>RA</strong> therapies: the details can be found in this brochure.<br />
As always, thank you for your continued support. We hope you have a fantastic time at <strong>ACR</strong> <strong>2023</strong>!<br />
Kind regards,<br />
Dr Grace Wright<br />
PS. Make sure you get all the insights from this <strong>ACR</strong> by downloading our other highlights brochures, and if you<br />
want to see the top picks for Lupus head on over to www.lupus-forum.com where you’ll find the top <strong>ACR</strong> picks<br />
and their top abstracts in the field of lupus therapeutics.<br />
Register for FREE content at<br />
www.cytokinesignalling.com<br />
Follow us at:<br />
Cytokine Signalling Forum<br />
SPONSORSHIP AND UNRESTRICTED<br />
EDUCATIONAL G<strong>RA</strong>NTS FROM<br />
DEVELOPED UNDER<br />
THE AUSPICES OF THE
KEY:<br />
H<br />
<strong>Highlights</strong><br />
ABST<strong>RA</strong>CT SESSION<br />
POSTER SESSION<br />
SCIENTIFIC SESSION<br />
Key Presentations<br />
Saturday, 11 November <strong>2023</strong><br />
08:00 –<br />
15:45<br />
11:10 –<br />
11:25<br />
11:30 –<br />
11:45<br />
BASIC & CLINICAL RESEARCH CONFERENCE<br />
Chairs: Anne-Marie Malfait, Tuhina Neogi<br />
Focus on Specific Rheumatic and Musculoskeletal Diseases<br />
(RMDs) Part 1: Rheumatoid Arthritis – Mechanistic Insights<br />
Camilla Svensson<br />
Focus on Specific Rheumatic and Musculoskeletal Diseases<br />
(RMDs) Part 1: Rheumatoid Arthritis – Clinical Insights<br />
Yvonne C. Lee<br />
Sunday, 12 November <strong>2023</strong><br />
09:00 –<br />
11:00<br />
0002<br />
09:00 –<br />
11:00<br />
0013<br />
09:00 –<br />
11:00<br />
0206<br />
09:00 –<br />
11:00<br />
0294<br />
09:00 –<br />
11:00<br />
0414<br />
09:00 –<br />
11:00<br />
0424<br />
B CELL BIOLOGY & TARGETS IN AUTOIMMUNE<br />
& INFLAMMATORY DISEASE POSTER<br />
Population Pharmacokinetic and Pharmacodynamic Analyses<br />
of Obexelimab in Healthy Volunteers and in Patients with<br />
Rheumatoid Arthritis or IgG4-Related Diseases<br />
Xiadong Wang<br />
GENETICS, GENOMICS & PROTEOMICS POSTER<br />
A Proliferating T Cell Signature in Blood Is Associated<br />
with Response to JAK Inhibitor Therapy in Rheumatoid<br />
Arthritis Patients<br />
Mehreen Elahee<br />
INFECTION-RELATED RHEUMATIC DISEASE<br />
POSTER<br />
Risk of Hepatitis B Virus Reactivation in Patients with<br />
Rheumatoid Arthritis Receiving JAK Inhibitor or IL-6 Inhibitor:<br />
A Systematic Review and Meta-Analysis<br />
Akhil Sood<br />
MUSCLE BIOLOGY, MYOSITIS & MYOPATHIES –<br />
BASIC & CLINICAL SCIENCE POSTER I<br />
Tofacitinib Treatment in Rheumatoid Arthritis Is Associated<br />
with Increased Lower Limb Muscle Volume: The Rheumatoid<br />
Arthritis and Muscle (<strong>RA</strong>MUS) Study<br />
Joshua L. Bennett<br />
<strong>RA</strong> – DIAGNOSIS, MANIFESTATIONS, AND<br />
OUTCOMES POSTER I<br />
Association of a Treat-to-Target Management Approach with<br />
Physician and Patient Reported Outcomes Among Real –<br />
World Patients with Rheumatoid Arthritis Receiving Advanced<br />
Therapy in Europe<br />
Douglas White<br />
<strong>RA</strong> – TREATMENTS POSTER I<br />
Real-World Effectiveness of Upadacitinib in Patients<br />
with Moderate/Severe Rheumatoid Arthritis: 6-Month<br />
Data from the Observational UPHOLD Study<br />
Andrew Östör<br />
H<br />
0426<br />
0429<br />
0430<br />
0432<br />
0434<br />
0437<br />
0441<br />
0444<br />
0448<br />
0450<br />
0451<br />
0452<br />
0458<br />
0459<br />
The Clinical Efficacy of Switching Therapy Between<br />
Biological Agents and JAK Inhibitors in the Patients with<br />
Rheumatoid Arthritis<br />
Tomokazu Choshi<br />
Direct and Indirect Effects of Upadacitinib or<br />
Adalimumab on Pain in Rheumatoid Arthritis:<br />
Results from a Randomized Phase 3 Study<br />
Peter C. Taylor<br />
A Multicenter, Real-world Clinical Data Study of the Use<br />
of JAK Kinase Inhibitors in a Large Cohort of Patients with<br />
Rheumatoid Arthritis<br />
Maria Lopez-Lasanta<br />
Predictors of Use, Survival and Safety of Tofacitinib Monotherapy<br />
vs. in Combination with CsDMARDs in Daily Clinical Practice<br />
Rodolfo Perez-Alamino<br />
Effects of b/tsDMARDs on Non-inflammatory Pain in Patients<br />
with Rheumatoid Arthritis -ANSWER Longitudinal Cohort Study-<br />
Mai Yamashita<br />
Comparative Safety of Biologic and Targeted Synthetic<br />
Disease Modifying Anti-Rheumatic Drugs for Cardiovascular<br />
Outcomes in Rheumatoid Arthritis<br />
Xavier Sendaydiego<br />
Outcomes in Patients with Rheumatoid Arthritis Initiating<br />
Therapy with Etanercept, Adalimumab, or Janus Kinase<br />
Inhibitors<br />
Dimitrios Pappas<br />
Safety, Tolerability, and Pharmacokinetics of a<br />
Novel Synthetic Disease Modifying Antirheumatic<br />
Drug, TCK-276, After Single Ascending Dose in Healthy<br />
Subjects and Multiple Ascending Doses in Patients<br />
with Rheumatoid Arthritis<br />
Yoshinori Tsumura<br />
Cardioprotective Impact of JAKi, Tofacitinib, on CV Risk in<br />
Rheumatoid Arthritis: JAKi CV Risk Impact Study<br />
Ashit Syngle<br />
Baricitinib versus TNF-inhibitors in Patients<br />
with Active Rheumatoid Arthritis After Failure of<br />
csDMARDs: A Pragmatic, Multicenter, Real-Life Study<br />
in a Treat-to-Target Setting<br />
Martinus Van de Laar<br />
Long-term Clinical Profile of Filgotinib in Patients with<br />
Rheumatoid Arthritis by Cardiovascular Risk Factors: A Post<br />
Hoc Subgroup Analysis<br />
Maya Buch<br />
Real Life Safety and Survival of Targeted Therapies in<br />
Arthritis Patients over Age of 65<br />
Elena Grau Garcia<br />
Drug Switching Due to Inefficacy in Rheumatoid Arthritis<br />
Patients Treated with Biological and Targeted Therapies.<br />
Daily Clinical Experience<br />
Maria Rodriguez Laguna<br />
Upadacitinib Monotherapy versus Methotrexate<br />
in Patients with Rheumatoid Arthritis: Efficacy<br />
and Safety Through 5 Years in the SELECT-EARLY<br />
Randomized Controlled Trial<br />
Ronald van Vollenhoven<br />
H<br />
H<br />
H<br />
H
KEY:<br />
H<br />
<strong>Highlights</strong><br />
ABST<strong>RA</strong>CT SESSION<br />
POSTER SESSION<br />
SCIENTIFIC SESSION<br />
12:00 –<br />
13:00<br />
12S127<br />
16:00 –<br />
17:00<br />
12S155<br />
16:00 –<br />
17:30<br />
0839<br />
0840<br />
RHEUMATOID ARTHRITIS<br />
Chairs: Percio Gulko, Anne-Marie Malfait<br />
No Pain and Much to Gain: Mechanisms and Targets of<br />
Pain in Rheumatic Diseases<br />
Ru-Rong Ji, Rachel Miller, Theodore Price<br />
EPIDEMIOLOGY, HEALTH POLICY AND OUTCOMES<br />
Chairs: Kristi Kuhn, Michael Weisman<br />
FDA Update on Safety Issues in the Treatment of<br />
Rheumatic Diseases<br />
Eric Gapud, Nadia Habal, Anil Rajpal<br />
<strong>RA</strong> – TREATMENTS I: NOVEL <strong>RA</strong> TREATMENTS<br />
& MECHANISMS OF ACTION<br />
Efficacy and Safety of Nipocalimab in Patients<br />
with Moderate to Severe Active Rheumatoid Arthritis<br />
(<strong>RA</strong>): The Multicenter, Randomized, Doubleblinded,<br />
Placebo-controlled Phase 2a IRIS-<strong>RA</strong> Study<br />
Peter C. Taylor<br />
Head-to-Head Comparison of TLL-018 and<br />
Tofacitinib in Patients with Active Rheumatoid<br />
Arthritis: Final Results from a Phase IIa Study<br />
Xiaofeng Zeng<br />
Monday, 13 November <strong>2023</strong><br />
09:00 –<br />
11:00<br />
1017<br />
09:00 –<br />
11:00<br />
1215<br />
09:00 –<br />
11:00<br />
0971<br />
0973<br />
HEALTHCARE DISPARITIES IN RHEUMATOLOGY<br />
POSTER II: SOCIOECONOMIC DETERMINANTS<br />
Cross Country Differences in b/tsDMARD Prescription<br />
Behavior: Associations Between Socioeconomics,<br />
Real World b/tsDMARD Use and Disease Outcomes<br />
Isabell Nevins<br />
PATIENT OUTCOMES, PREFERENCES, &<br />
ATTITUDES POSTER II<br />
Efficacy of Pharmacological Interventions: A Systematic<br />
Review Informing the <strong>2023</strong> EULAR Recommendations for<br />
the Management of Fatigue in People with Inflammatory<br />
Rheumatic and Musculoskeletal Diseases<br />
Bayram Farisogullari<br />
EPIDEMIOLOGY & PUBLIC HEALTH POSTER II<br />
Network Meta Analyses of the Effectiveness and Safety<br />
Profiles of Janus Kinase Inhibitors and Biologic Agents<br />
in Treating Children with Nonsystemic Juvenile Idiopathic<br />
Arthritis (nsJIA)<br />
Bin Huang<br />
Real-World Comparative Effectiveness Study of Janus<br />
Kinase Inhibitors Compared to Biologic Disease<br />
Modifying Antirheumatic Drugs in Korean Patients<br />
with Rheumatoid Arthritis<br />
Soo-Kyung Cho<br />
H<br />
H<br />
09:00 –<br />
11:00<br />
1314<br />
1323<br />
1325<br />
1326<br />
1328<br />
1329<br />
1332<br />
1337<br />
1343<br />
1344<br />
09:00 –<br />
11:00<br />
1379<br />
14:00 –<br />
15:00<br />
13M140<br />
<strong>RA</strong> – TREATMENTS POSTER II<br />
Safety Results from a Phase 1 Double-blind Randomized<br />
Clinical Trial of Allogeneic Mesenchymal Stem Cells in Early <strong>RA</strong><br />
Nora Singer<br />
Distinct Treatment Responses in Patients with Rheumatoid<br />
Arthritis Receiving Filgotinib 200 Mg over 12 Months: A Post<br />
Hoc Analysis of FINCH 1<br />
Peter C. Taylor<br />
Integrated Safety Analysis of Filgotinib in Patients<br />
with Moderate to Severe Active Rheumatoid Arthritis<br />
with a Maximum Exposure of 8.3 Years<br />
Kevin Winthrop<br />
Safety and Efficacy of Upadacitinib in Patients with H<br />
Rheumatoid Arthritis Refractory to Biologic DMARDs:<br />
Results Through Week 204 from the SELECT-CHOICE Study<br />
Andrea Rubbert-Roth<br />
Switching Biologics or Janus Kinase Inhibitors Is Effective in<br />
Difficult-to-treat Rheumatoid Arthritis, Regardless of Inflammation<br />
Katsuaki Onishi<br />
R851, a Potent Second Generation I<strong>RA</strong>K1 and I<strong>RA</strong>K4<br />
Inhibitor Suppresses IL-6 in Vitro and in Vivo for the<br />
Treatment of Rheumatoid Arthritis<br />
Simon Shaw<br />
Patient-Reported Outcomes, Disease Activity<br />
and Safety in 798 Patients with <strong>RA</strong> Treated with<br />
Filgotinib: Up to 1-Year Interim Results from a<br />
Prospective Observational Study (FILOSOPHY)<br />
Gerd Burmester<br />
Effect of Tofacitinib Therapy on Angiotensin Converting<br />
Enzyme Activity in Rheumatoid Arthritis<br />
Zoltan Szekanecz<br />
Cardiovascular (CV) and Malignancy Events in<br />
the Filgotinib Rheumatoid Arthritis (<strong>RA</strong>) Clinical<br />
Development Program up to 8.3 Years<br />
Xavier Mariette<br />
Efficacy and Safety of JAK Inhibitors in Difficult to Treat<br />
Rheumatoid Arthritis in Clinical Practice<br />
Omar Al Tabaa<br />
SJÖGREN’S SYNDROME – BASIC & CLINICAL<br />
SCIENCE POSTER I<br />
Population Pharmacokinetic/Pharmacodynamic<br />
Modeling of Dazodalibep, a CD40L Antagonist,<br />
in Healthy Volunteers and Patients with Rheumatoid<br />
Arthritis and Sjogren’s Syndrome<br />
Kenneth Der<br />
RHEUMATOID ARTHRITIS<br />
Chairs: Susan Goodman, Diane Horowitz<br />
Precision Clinical Trial Design in Rheumatoid Arthritis<br />
Costantino Pitzalis<br />
H<br />
H<br />
H<br />
H<br />
H<br />
09:00 –<br />
11:00<br />
1132<br />
MISCELLANEOUS RHEUMATIC &<br />
INFLAMMATORY DISEASES POSTER II<br />
Preclinical Profiles of FZ007-119, a Highly Potent and<br />
Selective Tyk2 Inhibitor, for the Treatment of Immune<br />
Mediated Inflammatory Disease<br />
Shiqun Zhang<br />
16:00 –<br />
17:30<br />
1676<br />
<strong>RA</strong> – TREATMENTS II: <strong>RA</strong> TREATMENT SAFETY<br />
Tofacitinib Accelerates in Vitro Clot Formation and Delays<br />
Clot Lysis in Rheumatoid Arthritis Blood by Enhancement of<br />
Macrophage TLR4 Mediated Cytokine Responses – a New<br />
Angle on Thrombosis with JAKi in Rheumatology<br />
Paula David
KEY:<br />
H<br />
<strong>Highlights</strong><br />
ABST<strong>RA</strong>CT SESSION<br />
POSTER SESSION<br />
SCIENTIFIC SESSION<br />
Tuesday, 14 November <strong>2023</strong><br />
09:00 –<br />
11:00<br />
2033<br />
09:00 –<br />
11:00<br />
2095<br />
09:00 –<br />
11:00<br />
2142<br />
2143<br />
2144<br />
2145<br />
2146<br />
2147<br />
2150<br />
2153<br />
2155<br />
PATIENT OUTCOMES, PREFERENCES,<br />
& ATTITUDES POSTER III<br />
Sex Differences in Patient-Reported Outcomes in<br />
Patients with Rheumatoid Arthritis After Starting a New<br />
Disease-Modifying Antirheumatic Medication<br />
John Davis<br />
<strong>RA</strong> – DIAGNOSIS, MANIFESTATIONS,<br />
AND OUTCOMES POSTER III<br />
Integrated Analysis of Gene Expression and Methylation<br />
Identifies Biomarkers Associated with Mode of Action of<br />
Upadacitinib Treatment in Rheumatoid Arthritis<br />
Iain McInnes<br />
<strong>RA</strong> – TREATMENTS POSTER III<br />
Adherence Patterns in Rheumatoid Arthritis Patients<br />
Receiving a Janus Kinase (JAK) Inhibitor or a Tumor Necrosis<br />
Factor α Inhibitor (TNFi) After the Addition of a Black Box<br />
Warning to JAK Inhibitors<br />
Samantha Delgado<br />
Efficacy of Filgotinib in Patients with Rheumatoid Arthritis:<br />
Week 156 Results from a Long-term Extension Study<br />
Maya Buch<br />
Pharmacodynamic Effects of Nipocalimab<br />
in Patients with Moderate to Severe Active<br />
Rheumatoid Arthritis (<strong>RA</strong>): Results from the<br />
Multicenter, Randomized, Double-blinded,<br />
Placebo-controlled Phase 2A IRIS-<strong>RA</strong> Study<br />
Rohit Panchakshari<br />
Patterns of Use, Effectiveness, Persistence and Cardiovascular<br />
Risk in Patients with Rheumatic Diseases Treated with<br />
Upadacitinib in a Real-world Setting. UPAREAL Study<br />
Alicia Garcia Dorta<br />
After JAK Inhibitor Failure, “Switching” or “Cycling”?<br />
Pablo Francisco Muñoz Martínez<br />
Safety and Effectiveness in Cycling Between Non-Selective<br />
and Selective JAKi in a Multi-Center Registry of Rheumatoid<br />
Arthritis in the Middle East<br />
Rajaie Namas<br />
Novel Biologic IRL201805 Inhibits Osteoclastogenesis in<br />
Monocytic Cells from <strong>RA</strong> Patients<br />
Yuriko Yamamura<br />
Effects of One-year Tofacitinib Therapy on Angiogenic<br />
Biomarkers in Rheumatoid Arthritis<br />
Zoltan Szekanecz<br />
The Impact of Filgotinib on Disease Activity Outcomes with<br />
Concomitant Pain Control in the Phase 3 FINCH Studies<br />
Peter C. Taylor<br />
H<br />
2157<br />
2162<br />
2167<br />
2174<br />
2176<br />
09:00 –<br />
11:00<br />
2413<br />
12:00 –<br />
13:00<br />
14T131<br />
14:00 –<br />
15:00<br />
14T144<br />
16:00 –<br />
17:30<br />
2505<br />
Exploratory Analysis of the Mechanisms of Action H<br />
of the Potential Analgesic Effect of Tofacitinib and<br />
Adalimumab over Placebo in Patients with Rheumatoid<br />
Arthritis: Results of a Mediation Modeling Analysis<br />
Maxime Dougados<br />
Safety and Efficacy of Filgotinib: An Update from<br />
the DARWIN 3 Phase 2 Long-term Extension with<br />
a Maximum of 8.2 Years of Exposure<br />
Paul Emery<br />
24-week, Post-Marketing Surveillance Analysis of Upadacitinib<br />
in Japanese Patients with Rheumatoid Arthritis (Encore)<br />
Tatsuya Atsumi<br />
JAK Inhibitors in Rheumatoid Arthritis-Interstitial Lung Disease.<br />
National Multicenter Study of 73 Patients, 55 of Baricitinib<br />
Ana Serrano-Combarro<br />
Cellular and Proteomic Changes Following<br />
Administration of Peresolimab, in a Phase 2a Trial<br />
in Rheumatoid Arthritis<br />
Robert J. Benschop<br />
VASCULITIS – NON-ANCA-ASSOCIATED<br />
& RELATED DISORDERS POSTER III<br />
Janus Kinase Inhibitors in Giant Cell Arteritis in Clinical Practice.<br />
Real World Clinical Practice Study and Literature Review<br />
Fernando Lopez<br />
RHEUMATIC MANIFESTATIONS OF<br />
SYSTEMIC DISEASES<br />
Chairs: Sarfaraz Hasni, Maureen McMahon<br />
Cardiovascular Rheumatology: Lessons Learned from<br />
Targeting Inflammation to Modulate CV Risk<br />
Ian Bruce, Johan Frostegard, Susan Manzi<br />
RHEUMATOID ARTHRITIS<br />
Chair: Laura Donlin<br />
Reconstructing Rheumatoid Arthritis Through Space<br />
and Time. New Insights into <strong>RA</strong> Pathology from the<br />
AMP <strong>RA</strong>/SLE Consortium<br />
Andrew Filer, Deepak Rao, Kathryn Weinand<br />
CYTOKINES & CELL T<strong>RA</strong>FFICKING<br />
Discovery of First-in-Class I<strong>RA</strong>K4 Scaffolding Inhibitors for<br />
the Treatment of Inflammatory Disorders<br />
Kate Byth<br />
Wednesday, 15 November <strong>2023</strong><br />
08:00 –<br />
09:00<br />
15W109<br />
RHEUMATOID ARTHRITIS<br />
Chairs: Elizabeth Park, Michael Weinblatt<br />
<strong>RA</strong> Treatment: Are We Good Enough?<br />
Paul Emery, Bryant England<br />
H<br />
H<br />
Register for FREE content at www.cytokinesignalling.com<br />
DEVELOPED UNDER<br />
THE AUSPICES OF THE<br />
Follow us at:<br />
Cytokine Signalling Forum
Change language